ELI LILLY & Co is 99.6x more valuable than BIOMARIN PHARMACEUTICAL INC by market capitalization ($1.070 T vs $10.74 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BMRN | LLY |
|---|---|---|
| Market cap | $10.74 B | $1.070 T |
| US-listed rank | #903 | #10 |
| Revenue (latest FY) | $3.22B | $65.18B |
| Net income (latest FY) | $348.90M | $20.64B |
| Net margin | 10.8% | 31.7% |
| P/E (trailing FY) | 30.8 | 51.8 |
| SEC filings | 2,709 | 989 |
ELI LILLY & Co is 99.6x more valuable than BIOMARIN PHARMACEUTICAL INC by market capitalization ($1.070 T vs $10.74 B).
In their latest fiscal years, BIOMARIN PHARMACEUTICAL INC reported $3.22B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: BIOMARIN PHARMACEUTICAL INC and ELI LILLY & Co, or browse the full rankings.